EMA Sticks With JN.1 Variant For COVID-19 Vaccines, Despite US FDA's Choice of KP.2

 
• By Ian Schofield

Targeting the JN.1 subvariant of the SARS-CoV-2 virus will facilitate timely vaccination campaigns in Europe to help reduce the burden of disease associated with COVID-19, according to the EU regulator.

new variant and mutation of coronavirus, covid 19 strain, virus protein infection, 3D Illustration
COVID-19 vaccines must be regularly updated to target virus variants • Source: Shutterstock

More from Europe

More from Geography